SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
27-Oct-23 4:13 PM View: | Scopa James Paul Director | Aligos Therapeutics, Inc. (ALGS) | 25-Oct-23 | Grant | 183,083 | $0.76 | $138,557.00 | 100% 0 to 183.08K | |
27-Oct-23 4:14 PM View: | Blatt Lawrence Chief Executive Officer Director | Aligos Therapeutics, Inc. (ALGS) | 25-Oct-23 | Grant | 610,277 | $0.76 | $461,858.00 | 40% 1.51M to 2.12M | |
27-Oct-23 4:15 PM View: | Nuechterlein Carole Director 10% Owner | Aligos Therapeutics, Inc. (ALGS) | 25-Oct-23 | Private Purchase | 7,933,600 | $0.76 | $6,004,150.00 | 257% 3.09M to 11.03M | |
15-Jun-21 4:43 PM View: | Woiwode Thomas Director | Aligos Therapeutics, Inc. (ALGS) | 11-Jun-21 | Acquisition (other) | 18,102 | -- | -- | < 1% 2.81M to 2.83M | |
15-Jun-21 4:43 PM View: | Woiwode Thomas Director | Aligos Therapeutics, Inc. (ALGS) | 11-Jun-21 | Disposition (other) | 485,979 | -- | -- | (17%) 2.81M to 2.32M | |
15-Jun-21 4:43 PM View: | Woiwode Thomas Director | Aligos Therapeutics, Inc. (ALGS) | 11-Jun-21 | Acquisition (other) | 2,226 | -- | -- | < 1% 2.83M to 2.83M | |
15-Jun-21 4:43 PM View: | Woiwode Thomas Director | Aligos Therapeutics, Inc. (ALGS) | 11-Jun-21 | Disposition (other) | 18,102 | -- | -- | (< 1%) 2.83M to 2.81M | |
28-Apr-21 5:00 PM View: | Woiwode Thomas Director | Aligos Therapeutics, Inc. (ALGS) | 26-Apr-21 | Acquisition (other) | 2,226 | -- | -- | < 1% 3.31M to 3.31M | |
28-Apr-21 5:00 PM View: | Woiwode Thomas Director | Aligos Therapeutics, Inc. (ALGS) | 26-Apr-21 | Disposition (other) | 18,105 | -- | -- | (< 1%) 3.31M to 3.29M | |
28-Apr-21 5:00 PM View: | Woiwode Thomas Director | Aligos Therapeutics, Inc. (ALGS) | 26-Apr-21 | Acquisition (other) | 18,105 | -- | -- | < 1% 3.29M to 3.31M | |
28-Apr-21 5:00 PM View: | Woiwode Thomas Director | Aligos Therapeutics, Inc. (ALGS) | 26-Apr-21 | Disposition (other) | 485,979 | -- | -- | (15%) 3.29M to 2.81M | |
22-Oct-20 4:12 PM View: | Wellington Biomedical Innov... 10% Owner | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 1,906,190 | -- | -- | 100% 0 to 1.91M | |
20-Oct-20 4:56 PM View: | Quan Lucinda Y. See Remarks | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 9,258 | -- | -- | 2% 375.55K to 384.81K | |
20-Oct-20 4:58 PM View: | Versant Venture Capital Vi,... 10% Owner | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 662,444 | -- | -- | 27% 2.43M to 3.09M | |
20-Oct-20 4:59 PM View: | Vivo Capital Viii, LLC 10% Owner | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Purchase | 550,000 | $15.00 | $8,250,000.00 | 18% 3.0M to 3.55M | |
22-Oct-20 4:31 PM View: | Novo A/s 10% Owner | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 2,414,560 | -- | -- | 100% 0 to 2.41M | |
20-Oct-20 4:53 PM View: | Beigelman Leonid President Director | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 273,057 | -- | -- | 22% 1.24M to 1.51M | |
20-Oct-20 4:57 PM View: | Symons Julian A. See Remarks | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 18,517 | -- | -- | 5% 375.55K to 394.06K | |
20-Oct-20 4:58 PM View: | Versant Venture Capital Vi,... 10% Owner | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Purchase Duplicate | 200,000 | $15.00 | $3,000,000.00 | 6% 3.09M to 3.29M | |
20-Oct-20 5:00 PM View: | Woiwode Thomas Director | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 3,092,340 | -- | -- | 100% 0 to 3.09M | |
20-Oct-20 5:00 PM View: | Woiwode Thomas Director | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Purchase Duplicate | 200,000 | $15.00 | $3,000,000.00 | 6% 3.09M to 3.29M | |
22-Oct-20 4:31 PM View: | Novo A/s 10% Owner | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Purchase | 200,000 | $15.00 | $3,000,000.00 | 8% 2.41M to 2.61M | |
20-Oct-20 4:55 PM View: | Nuechterlein Carole Director | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 3,092,340 | -- | -- | 100% 0 to 3.09M | |
20-Oct-20 4:58 PM View: | Versant Venture Capital Vi,... 10% Owner | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 2,429,900 | -- | -- | 100% 0 to 2.43M | |
20-Oct-20 4:59 PM View: | Vivo Capital Viii, LLC 10% Owner | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 2,997,030 | -- | -- | 100% 0 to 3.0M | |
20-Oct-20 4:55 PM View: | Blatt Lawrence Chief Executive Officer | Aligos Therapeutics, Inc. (ALGS) | 20-Oct-20 | Conversion | 273,058 | -- | -- | 22% 1.24M to 1.51M |